EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anticancer Activity of Annonacin and Its Synergistic Enhancement of Docetaxel Efficacy in Prostate Cancer

Yunbei Xiao iD, Qinquan Wang, Chen Sun iD, Haoran Zou, Xiaozhi Cheng, Ruijie Yao, Huiliang Zhou iD

Journal of Cellular and Molecular Medicine · 2025

DOI: 10.1111/jcmm.70972 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Yunbei Xiao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Andrology and Sexual Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Docetaxel, Prostatic Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Plan Project of Wenzhou Municipality, Wenzhou Association for Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PCa) is the second most prevalent malignancy in men, and therapeutic options become severely limited once androgen deprivation therapy (ADT) fails. This study evaluated the antitumor activity of Annonacin, a natural acetogenin, alone or in combination with docetaxel (DTX) in PCa. The antitumor effects and underlying mechanisms of Annonacin and/or DTX were investigated in DU145 cells and a xenograft mouse model by assessing proliferation, migration, apoptosis, colony formation, DNA damage and FAK expression and distribution. Through an integrated strategy combining network pharmacology and a series of in vitro assays, the findings demonstrated that Annonacin exerts significant antitumor activity by inducing DNA damage and downregulating FAK expression and localisation. Co‐treatment with DTX further enhanced these effects, with combination index (CI) values < 1, indicating strong synergism. In vivo, the combination therapy achieved more than 74% tumour growth inhibition ( p < 0.0001), accompanied by increased tumour cell death, reduced Ki‐67 expression and elevated γ‐H2AX levels. Collectively, these findings demonstrate that Annonacin exerts potent antitumor activity and synergistically enhances DTX efficacy by promoting DNA damage and suppressing FAK signalling, supporting its potential as a promising adjuvant candidate for PCa treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DocetaxelProstatic NeoplasmsAntineoplastic AgentsMaleHumansAnimalsCell Line, TumorDrug SynergismCell ProliferationApoptosisXenograft Model Antitumor AssaysDNA DamageCell MovementMiceFocal Adhesion Kinase 1Mice, NudeMice, Inbred BALB CGene Expression Regulation, NeoplasticSignal Transduction

Stichwörter der Autor:innen

AnnonacinDNAanticancer activitycombination treatmentdocetaxelprostate cancer

Substanzen

DocetaxelFocal Adhesion Kinase 1Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Andrology and Sexual Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
  • Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.

ORCID-Profile: Yunbei Xiao, Chen Sun, Huiliang Zhou

Förderung

  • Science and Technology Plan Project of Wenzhou Municipality
  • Wenzhou Association for Science and Technology

Zitieren

APA

Xiao, Y., Wang, Q., Sun, C., Zou, H., Cheng, X., Yao, R., & Zhou, H. (2025). Anticancer Activity of Annonacin and Its Synergistic Enhancement of Docetaxel Efficacy in Prostate Cancer. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70972

Vancouver

Xiao Y, Wang Q, Sun C, Zou H, Cheng X, Yao R, et al. Anticancer Activity of Annonacin and Its Synergistic Enhancement of Docetaxel Efficacy in Prostate Cancer. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70972

BibTeX
@article{Xiao2025,
  author = {Xiao, Yunbei and Wang, Qinquan and Sun, Chen and Zou, Haoran and Cheng, Xiaozhi and Yao, Ruijie and Zhou, Huiliang},
  title = {Anticancer Activity of Annonacin and Its Synergistic Enhancement of Docetaxel Efficacy in Prostate Cancer},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2025},
  doi = {10.1111/jcmm.70972}
}
Kostenlos starten →